Given the emerging evidence that antiangiogenic agents modulate the tumor microenvironment (TME) and synergize with ICIs (21, 22), the combination of PD-1/PD-L1 inhibitors and antiangiogenic therapy is an attractive treatment strategy for EC patients with pMMR (5). Here, CD274 is linked to neoplasm.